Drug intelligence / Profile preview

AMEP + Synfoldin

Development stage: Unknown
Lead developer: BioAlliance
Administration: Intramuscular

Overview

AMEP + Synfoldin is an investigational oncology combination being developed for the treatment of invasive and metastatic melanoma, originating from BioAlliance Pharma’s targeted therapy platform aimed at overcoming drug resistance in solid tumors.[6][4] Public company documents list “AMEP®/Synfoldin” as a melanoma program in clinical and preclinical phases, but do not disclose the precise molecular identities, targets, or mechanisms of action of either AMEP or Synfoldin.[6][4] Based on available information, AMEP + Synfoldin should be considered an early‑stage, experimental melanoma-directed combination therapy with undisclosed modality, pharmacology, and mechanism.

Other names: AMEP/SynfoldinAMEP Synfoldin

Targets

Neuraminidase

Beyond the preview

Go deeper on AMEP + Synfoldin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMEP + Synfoldin.

Explore the full profile